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ABSTRACT A critical appraisal and clinical application of Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated 
heart failure with cardiorenal syndrome. N. Engl. J. Med. 2012;367:2296-2304. doi: 10.1056/NEJMoa1210357 
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Clinical Context 
The patient is an 80-year-old Caucasian man with past medical history of hypertension, type 2 diabetes mellitus, 
heart failure with preserved ejection fraction, and status post living donor renal transplant in 2010. He described 
symptoms of acute onset nausea and vomiting. His physical exams showed tense ascites and elevated jugular 
venous pressure suggestive of fluid overload. His labs showed a serum creatinine of 2.5, elevated from a baseline 
of 1. Due to a calculated FeNa <1% and paracentesis of ascitic fluid with a serum-albumin ascites-albumin ratio of 
<1.1, he was diagnosed with pre-renal acute kidney injury (AKI) secondary to acute decompensated heart failure 
and was admitted to the in-patient floor for management of cardiorenal syndrome type 1 by diuresis. 
Clinical Question 
Is ultrafiltration superior to pharmacologic diuresis in management of acute cardiorenal syndrome? 
Research Article 
Bart BA, Goldsmith SR, Lee KL, et al. Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N. Engl. J. Med. 
2012;367:2296-2304. doi: 10.1056/NEJMoa1210357 
Literature Review 
Type 1 cardiorenal syndrome occurs when AKI develops secondary to acute decompensation of heart function1. Volume overload 
contributes to AKI through several mechanisms: renal venous congestion, neurohormonal activation, intrarenal microvascular 
changes and cellular dysregulation1,2. A combination of fluid overload and renal injury in cardiorenal syndrome poses a therapeutic 
challenge. Loop diuretics have been the cornerstone treatment for congestion and volume overload in patients with acute CHF and 
cardiorenal syndrome1,3,4. However, limitations to this method include diuretic resistance, neuro-hormonal activation and worsening 
renal function contributing to persistent congestion. These limitations have been correlated with poor outcomes, including re-
hospitalization and increased mortality3-5. Alternative treatments are being investigated to determine if there are more effective 
therapies with better long-term outcomes than pharmacological diuresis.  
CHOONG G. Critical appraisal and clinical application of Bart BA, Goldsmith SR, Lee KL, et al. 
Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med. 2012;367:2296-
2304. 
 





http://digitalcommons.wayne.edu/crp, © 2016 The Author(s) 
2 Licensed under Creative Commons Attribution Non-Commercial 4.0 
 
Articles used to assess this question were found on Pubmed using the keywords “cardiorenal syndrome treatment” and a filtered 
search set that included clinical trials, meta-analyses, clinical and comparative studies. The search yielded 65 articles. The chosen 
article2 published the results of the “Cardiorenal Rescue Study in Acute Decompensated Heart Failure” (CARRESS-HF) trial, which 
compared the standard treatment for cardiorenal syndrome, called pharmacologic diuresis, against a newer method called 
ultrafiltration. It was the most recent randomized clinical trial that used a head-to-head comparison of different methods of diuresis. 
Other studies found using these search criteria examined specific novel prognostic markers or new methods of treatment (e.g. ACE 
inhibitors), or simply did not investigate individuals with cardiorenal syndrome. Prior to this study, the UNLOAD trial6 was the largest 
randomized control trial (n=200) comparing ultrafiltration and intravenous diuretics in patients with acute decompensated heart 
failure and fluid overload. This study showed a benefit with ultrafiltration in the first 48 hours, improved weight loss and decreased 
rate of re-hospitalization in patients with acute heart failure. The data directly contradicts the results of the CARRESS-HF trial2. 
Though both studies are similarly designed, there are some distinct differences. The UNLOAD trial did not enroll individuals with AKI 
due to cardiorenal syndrome nor did they have a strict pharmacologic algorithm. In contrast, the CARRESS-HF trial had prolonged 
ultrafiltration. Recent trials suggest ultrafiltration is an appropriate and safe method for individuals with volume overload1,7, and 
that rising creatinine during treatment was not a poor prognostic marker8. The RAPID-CHF trial, performed by the same group that 
conducted the CARRESS-HF trial, studied a significantly smaller population (n=40), but determined the safety and efficacy of 
ultrafiltration and pharmacologic diuresis compared to pharmacologic diuresis alone. However, due to the small sample size and 
cross-contamination of this study, it is difficult to draw strong conclusions about the superiority of one method over the other. 
Additionally, several studies have shown that aggressive and early diuresis by ultrafiltration (CUORE trial9) or pharmacological 
diuresis10 despite rising creatinine levels was associated with decreased re-hospitalization and more stable renal function. Despite 
these studies, a recent review by Obi, et al.11 suggests that cardiorenal syndrome type 1 be initially managed with loop diuretics 
rather than ultrafiltration, supporting the conclusions of the chosen article. 
Critical Appraisal 
The article by Bart, et al.2 was a randomized controlled multicenter clinical trial conducted in 22 sites across the United States and 
Canada that compared stepped pharmacological diuresis with ultrafiltration (UF) in patients with cardiorenal syndrome. This study 
provides level 1B evidence using the Oxford and National Guidelines Clearinghouse criteria. 
The patient population consisted of 188 individuals who were admitted to hospital with acute decompensated heart failure, and 
who developed cardiorenal syndrome as defined as an increase in serum creatinine of >0.3 mg/dL from baseline. This definition has 
been used in other studies on type 1 cardiorenal syndrome7,8. Patients were required to have at least 2 of the following 
characteristics: 2+ peripheral edema, jugular venous pressure >10 cm water, or pulmonary edema or effusion as assessed by 
radiography. A notable exclusion criteria was creatinine >3.5 mg/dL, likely excluding any individuals with severe CKD. Other exclusion 
criteria included those who were hemodynamically unstable, requiring intravenous vasodilators or inotropic agents. These exclusion 
criteria were likely chosen because of the effects of these agents on renal perfusion, which may be altered with pharmacologic 
diuresis or ultrafiltration. The majority of those enrolled in the study were Caucasian (80%) and male (80%); this demographic differs 
from the general patient population served in the clinical context described above. 
Patients were randomly assigned to either UF or pharmacologic diuresis. The randomization method was appropriate as there was 
no significant difference in demographic characteristics between both treatment groups for most criteria. However, there were a 
significantly greater number of individuals in the UF group who had heart failure secondary to ischemic disease (p=0.007). There was 
no difference in ejection fractions between the groups. This may have contributed to the overall decreased benefit of the UF group 
as these patients may not have been able to tolerate the adverse effects of UF and likely have increased renal vascular 
atherosclerosis. Otherwise, all clinically relevant data was reported in this study. 
Confounding variables were decreased by stopping pharmacologic diuresis on anyone assigned to the UF group. Despite this, 30% of 
individuals on UF went on to receive pharmacologic diuresis, while only 6% in the pharmacological group underwent UF. This may 
have decreased the difference between treatment groups when assessing long-term outcomes. A significantly long median time to 
admission and randomization in the study (34 h) likely contributed to the increased cross-contamination between the treatment 
groups.  
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The UF method involved an Aquadex system for low-volume continuous veno-venous ultrafiltration with a goal net rate of diuresis 
of 4.8 L/d, a method chosen to improve hemodynamic stability. However, treatment was not titrated based on clinical response. In 
contrast, the pharmacologic method involved a high-dose intensity stepped algorithm to prevent variability within the treatment 
group, with titration of goal urine output 3-5 L/d. Clinical decongestion was scored based on jugular venous pressure, peripheral 
edema and a subjective measure of dyspnea. Treatment was continued until clinical improvement of congestion was seen. This was 
a big limitation of the study, because cessation of treatment was entirely subjective and clinical bias potentially affected treatment 
titration. This was significant for the UF method, as there was no set algorithm in place, which may have contributed to greater 
variability in this group. A knowledge bias may also have occurred, as physicians may have been more comfortable with 
pharmacologic diuresis rather than the use of the Aquadex system for UF. The study also did not require physicians to document 
their clinical reasoning for cessation of diuresis, which may have provided insight into any internal biases. 
An intention to treat analysis was appropriate in this study as this most resembles real-world application and guards against bias. All 
individuals excluded from data analysis were accounted for. The study used a last-observation-carried-forward method for their 
analysis when the patient died, or was discharged prior to the 96 hour analysis (total of 26 patients; 13 in each treatment group). 
This could have altered outcomes as the previous data carried forward may have masked the overall effect of the treatment at 
future time points. The primary outcome was a change in creatinine and weight together as a bivariate endpoint assessed 96 h after 
enrollment, which was not a patient-oriented outcome. There was a significant change in the bivariate end-point at 96 h (p=0.003) in 
UF compared to pharmacologic diuresis, primarily driven by the increase in creatinine of 0.3 mg/dL in the UF group. This is of 
questionable clinical significance, as a difference of 0.3 mg/dL may have greater clinical significance at creatinine of 1.0 than it does 
at a creatinine of 5.0. There was no significant difference in mean weight loss at any time point. In the first 48 hours there was 
significantly (P=0.003) more fluid removed in the UF group than the pharmacologic group. This may have been due to the more rapid 
and efficient removal of fluid in the UF group in the beginning of treatment, along with prolonged duration (median = 40 h) 
compared to pharmacologic diuresis which is more time-dependent to reach a steady state. 72% of individuals in the UF group 
experienced adverse events compared to 57% in the pharmacologic diuresis group. Therefore, the number of patients that would 
need to be treated with UF to result in one adverse event (number needed to harm) compared to pharmacological diuresis was 7, a 
relatively small number. Individuals in the UF group experienced more kidney failure, bleeding complications and intravenous-
catheter associated complications. The overall rate of re-hospitalization and mortality were similar in both treatment groups at 7 
and 60 days and there was no difference between composite rate of death or re-hospitalization for heart failure (UF 38%, 
pharmacologic diuresis 35%; p=0.96). By 60 days, creatinine levels were below baseline in both treatments, though pharmacological 
diuresis had more significantly (P=0.003) improved creatinine. 
Overall, the study by Bart, et al., a randomized clinical control trial, provided the best available evidence to determine the most 
efficacious therapy for management of cardiorenal syndrome type 1. Several limitations to the study included the lack of blinding of 
treatments, prolonged diuresis by UF, clinical bias and lack of graded algorithm for UF. All of these factors may have contributed to 
an underestimation of the overall benefit of UF in this study, as well as an increased number of adverse events. The transient rise in 
serum creatinine by 48 hours in the UF group was likely secondary to hemoconcentration, which has not been associated with poor 
prognosis8. Nevertheless, based on the number of adverse events in the UF group and increased associated cost with similar long-
term outcomes, it is reasonable that pharmacological diuresis continues to be the first-line therapy for patients with cardiorenal 
syndrome; a suggestion supported by the 2013 ACCF/AHA Guidelines4. These guidelines state that patients admitted with heart 
failure and significant fluid overload should be promptly treated with intravenous loop diuretics to reduce morbidity. Ultrafiltration 
may be considered for patients with obvious fluid overload to alleviate congestive symptoms and fluid weight. Possible use of a 
different protocol of UF diuresis in future studies may reveal a benefit with this therapy. Also, as this study was conducted in a 
primarily Caucasian population, it remains to be seen if these results are as applicable to populations that do not fit the 
demographics of this study. 
Clinical Application 
The patient fit within the criteria of the Bart, et al., study population, as he was a white male with cardiorenal 
syndrome (2+ pitting edema, elevated jugular venous pressure) and creatinine <3.5 mg/dL on admission to 
hospital. Based on the findings by Bart, et al., initial treatment should be stepped pharmacologic diuresis for 
management of his volume overload. He was started on IV furosemide with a goal urine output of 2-3 L/d, slightly 
less than the goal urine output in the study of 3-5 L/d. After 7 days of diuresis with a net fluid loss of 8 kg, the 
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patient had clinical resolution of symptoms as determined by improvement of pitting edema and non-tense 
ascites. His serum creatinine improved from 2.50 to 2.20. He was transitioned to oral bumetanide and was 
discharged from the hospital to continue diuresis at home. 
Take Home Points: 
1.) First-line therapy for acute cardiorenal syndrome is stepped IV pharmacologic diuresis as patients experienced 
significantly less adverse outcomes and decreased creatinine levels compared to ultrafiltration. 
2.) Long-term outcomes with respect to weight, number of hospitalizations and mortality were not significantly 
different in patients in either treatment group. Therefore, consideration of ultrafiltration in patients who 
develop diuretic resistance may present a reasonable alternative therapy in these patients after a failure of a 
trial of pharmacologic diuresis. 
3.) Future studies investigating the role of ultrafiltration in acute cardiorenal syndrome should focus on 
developing an appropriate treatment algorithm that is based on individual responses to therapy and long-term 
outcomes. 
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